New hope for lung cancer patients with HER2 mutation: phase 3 trial launches
NCT ID NCT07178795
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study compares a new drug, BL-M07D1, to standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific HER2 gene change. About 440 adults will be randomly assigned to one of the two treatments. The goal is to see if the new drug helps people live longer without their cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.